PMC:7299399 / 46021-46849 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T219","span":{"begin":19,"end":26},"obj":"Body_part"}],"attributes":[{"id":"A219","pred":"fma_id","subj":"T219","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T145","span":{"begin":324,"end":332},"obj":"Disease"}],"attributes":[{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T424","span":{"begin":16,"end":18},"obj":"http://purl.obolibrary.org/obo/CLO_0050050"},{"id":"T425","span":{"begin":72,"end":77},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T426","span":{"begin":139,"end":140},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T427","span":{"begin":396,"end":397},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T389","span":{"begin":19,"end":26},"obj":"Chemical"},{"id":"T390","span":{"begin":156,"end":163},"obj":"Chemical"},{"id":"T391","span":{"begin":378,"end":382},"obj":"Chemical"},{"id":"T392","span":{"begin":383,"end":392},"obj":"Chemical"},{"id":"T393","span":{"begin":455,"end":460},"obj":"Chemical"},{"id":"T394","span":{"begin":770,"end":774},"obj":"Chemical"}],"attributes":[{"id":"A389","pred":"chebi_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A390","pred":"chebi_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/CHEBI_78059"},{"id":"A391","pred":"chebi_id","subj":"T391","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A392","pred":"chebi_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A393","pred":"chebi_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A394","pred":"chebi_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T63","span":{"begin":72,"end":95},"obj":"http://purl.obolibrary.org/obo/GO_0019048"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"LitCovid-sentences","denotations":[{"id":"T179","span":{"begin":274,"end":354},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"LitCovid-PubTator","denotations":[{"id":"691","span":{"begin":324,"end":332},"obj":"Disease"},{"id":"696","span":{"begin":540,"end":548},"obj":"Disease"}],"attributes":[{"id":"A691","pred":"tao:has_database_id","subj":"691","obj":"MESH:C000657245"},{"id":"A696","pred":"tao:has_database_id","subj":"696","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}

{"project":"2_test","denotations":[{"id":"32519842-32333836-158553","span":{"begin":27,"end":29},"obj":"32333836"},{"id":"32519842-32286790-158554","span":{"begin":269,"end":272},"obj":"32286790"},{"id":"32519842-30310233-158555","span":{"begin":775,"end":778},"obj":"30310233"}],"text":"y via the spike S1 protein.21 Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.129\n\nSpeeding up the Nanomedicine-Based Approaches for COVID-19 by In Silico Analysis\nCurrently, repurposing drug molecules is a key strategy for identifying approved or investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.130,131 There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.132,133 Therefore, these advantages have the potentia"}